Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK-02
- Development stage
- Unknown
- Lead developer
- NKGen Biotech, Inc.
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SNK-02 is an allogeneic natural killer (NK) cell therapy genetically engineered to express a chimeric antigen receptor (CAR) targeting the human epidermal growth factor receptor 2 (HER2). It is designed as an off-the-shelf, highly scalable product with high purity and cytotoxicity against HER2-expressing tumor cells. The therapy leverages SuperNK technology and is administered intravenously. Its primary mechanism involves direct recognition and killing of HER2-positive cancer cells via the CAR construct on NK cells. SNK-02 is being developed by NKGen Biotech for the treatment of various solid tumors that overexpress HER2, including breast cancer, gastric cancer, colorectal cancer, leiomyosarcoma, angiosarcoma, endometrial cancer, and undifferentiated pleomorphic sarcoma[1][4][5].
- Other names
- HER2-specific CAR NK cellHER-2-specific CAR NK cellHER 2-specific CAR NK cellanti-HER2-CAR SNK02anti-HER-2-CAR SNK02anti-HER 2-CAR SNK02
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SNK-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK-02.